2/2 #HansaBiopharma #KymeraTherapeutics #ArlettaPharma #FundaMentalPharma #LakefrontBiotherapeutics #PhoreMost #VerdivaBio #FormationBio #CNXTherapeutics #Capricor
zurl.co/gWFl0
zurl.co/gWFl0
Changing Faces: Pharma and biotech hires, June & July 2026
In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.
zurl.co
August 19, 2026 at 9:32 AM
Today PhoreMost announced its lead oncology programme PMC-001, a small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers and the appointment of Dr Gabriel Fox as CMO to lead its clinical development ➡️https://shorturl.at/i6amG
June 10, 2026 at 8:38 AM
Today PhoreMost announced its lead oncology programme PMC-001, a small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers and the appointment of Dr Gabriel Fox as CMO to lead its clinical development ➡️https://shorturl.at/i6amG
PhoreMost today announced the appointment of Dr Adam Gilbert to its SAB.
Adam will support PhoreMost to advance its portfolio of novel degrader therapeutics, and oversee the translation of molecular glues arising from its GlueSEEKER platform.
More: shorturl.at/Y4Ciy
Adam will support PhoreMost to advance its portfolio of novel degrader therapeutics, and oversee the translation of molecular glues arising from its GlueSEEKER platform.
More: shorturl.at/Y4Ciy
July 28, 2025 at 8:23 AM
PhoreMost today announced the appointment of Dr Adam Gilbert to its SAB.
Adam will support PhoreMost to advance its portfolio of novel degrader therapeutics, and oversee the translation of molecular glues arising from its GlueSEEKER platform.
More: shorturl.at/Y4Ciy
Adam will support PhoreMost to advance its portfolio of novel degrader therapeutics, and oversee the translation of molecular glues arising from its GlueSEEKER platform.
More: shorturl.at/Y4Ciy
PhoreMost published a new study showcasing the capabilities of its high-throughput GlueSEEKER® platform to accelerate the design and development of novel molecular glue degraders.
Read more ➡️https://shorturl.at/R9tbG
Read more ➡️https://shorturl.at/R9tbG
July 22, 2025 at 8:32 AM
PhoreMost published a new study showcasing the capabilities of its high-throughput GlueSEEKER® platform to accelerate the design and development of novel molecular glue degraders.
Read more ➡️https://shorturl.at/R9tbG
Read more ➡️https://shorturl.at/R9tbG
Today PhoreMost announced the appointments of Barbara Duncan as Chair and Stephen Dilly as Non-Executive Director of its Board, bringing leadership expertise to advance its degrader pipeline and the commercialisation of its GlueSEEKER® platform.
More: shorturl.at/u7Xdr
More: shorturl.at/u7Xdr
May 7, 2025 at 8:31 AM
Today PhoreMost announced the appointments of Barbara Duncan as Chair and Stephen Dilly as Non-Executive Director of its Board, bringing leadership expertise to advance its degrader pipeline and the commercialisation of its GlueSEEKER® platform.
More: shorturl.at/u7Xdr
More: shorturl.at/u7Xdr
#PhoreMost #molecularglue #drugdiscovery #GlueSEEKER #GlueSEEKERplatform #moleculargluedrugdiscovery #effectorproteins #E3ligases #BioRxiv #novelproteinproteininteractions #smallmoleculedrugs #biologicaldata #smallmoleculedevelopment #moleculargluetherapies
pharmatimes.com/news/phoremo...
pharmatimes.com/news/phoremo...
PhoreMost unveils platform to streamline molecular glue drug discovery - PharmaTimes
GlueSEEKER enables rational design of targeted protein degraders
pharmatimes.com
July 29, 2025 at 10:41 AM
PhoreMost Ltd – Uses its SITESEEKER® phenotypic screening/miniprotein platform to uncover new ligands and then turn them into small-molecule or biologic degraders. The 2022 multi-target collaboration with Arvinas explicitly feeds those hits into the PROTAC® Discovery Engine.
May 8, 2025 at 11:37 AM
PhoreMost Ltd – Uses its SITESEEKER® phenotypic screening/miniprotein platform to uncover new ligands and then turn them into small-molecule or biologic degraders. The 2022 multi-target collaboration with Arvinas explicitly feeds those hits into the PROTAC® Discovery Engine.
Feed: "PharmaTimes"
By: John Pinching on Tuesday, July 22, 2025
By: John Pinching on Tuesday, July 22, 2025
PhoreMost unveils platform to streamline molecular glue drug discovery
GlueSEEKER enables rational design of targeted protein degraders
pharmatimes.com
July 23, 2025 at 12:00 AM
Feed: "PharmaTimes"
By: John Pinching on Tuesday, July 22, 2025
By: John Pinching on Tuesday, July 22, 2025